Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06617481 · ClinicalTrials.gov registry record · Phase 2
PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence
A Phase 2 study of Prostate Cancer (Post Prostatectomy), sponsored by AdventHealth.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06617481 is a Phase 2 study of Prostate Cancer (Post Prostatectomy) that is actively recruiting participants, run by AdventHealth. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06617481, a Phase 2 study of Prostate Cancer (Post Prostatectomy), is actively recruiting participants, sponsored by AdventHealth.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Flotufolastat F-18, sold under the brand name Posluma, is a radioactive diagnostic agent for use with positron emission tomography (PET) imaging for prostate cancer. The research is being done to study the capability of 18F-rhPSMA-7.3 (flotufolastat F-18) PET scan to detect prostate cancer when there are very low levels of Prostate-Specific Antigen (PSA) following previous radical prostatectomy surgery.
Conditions Studied
Interventions
- DRUG 18F-rhPSMA-7.3 (Posluma)
Study Locations (1)
Florida
- AdventHealth - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-09-20 |
| Est. Completion | 2027-10-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06617481
The ClinicalTrials.gov registry entry for NCT06617481 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AdventHealth, which has 95 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer (Post Prostatectomy) appearing as the primary indexed condition, and to 1 intervention - of which 18F-rhPSMA-7.3 (Posluma) is the first listed.
NCT06617481 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06617481 about?
NCT06617481 is a clinical study titled "PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence". Flotufolastat F-18, sold under the brand name Posluma, is a radioactive diagnostic agent for use with positron emission tomography (PET) imaging for prostate cancer. The research is being done to study the capability of 18F-rhPSMA-7.3 (flotufolastat F-18) PET scan to detect prostate cancer when the...
What is the current status of trial NCT06617481?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2024-09-20. Estimated completion is 2027-10-10.
What conditions does trial NCT06617481 study?
This clinical trial studies the following conditions: Prostate Cancer (Post Prostatectomy).
What interventions are being tested in trial NCT06617481?
The interventions under investigation include: 18F-rhPSMA-7.3 (Posluma) (DRUG).
Who is sponsoring clinical trial NCT06617481?
This trial is sponsored by AdventHealth, which has 95 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06617481 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer (Post Prostatectomy)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.